Tiexin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tiexin Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jaeyoung Park
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, 30332, GA, USA
1 shared publication - Kevin S. McFarland
Cell Culture and Fermentation Sciences, BioPharmaceuticals Development R&D AstraZeneca Gaithersburg USA
1 shared publication - Michael Betenbaugh
Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore Maryland USA
1 shared publication - Qiong Wang
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
1 shared publication - Xiao Liu
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
1 shared publication - Yifeng Hu
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
1 shared publication
Latest Publications
- Open Access
- 2 August 2019
- Published by MDPI AG in Antibodies
- Vol. 8 (3) , 43
Design and Production of Bispecific Antibodies
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells. Structural diversity has been fast-growing in the bispecific antibody field, creating a plethora of novel bispecific antibody scaffolds, which provide great functional variety. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody. Unlike the conventional monoclonal antibodies, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. In this review, we focus on these two major bispecific types and describe recent advances in the design, production, and quality of these molecules, which will enable this important class of biologics to reach their therapeutic potential.
- 2 August 2019
- Published by MDPI AG in Antibodies
- Vol. 8 (3) , 43
Open AccessDesign and Production of Bispecific Antibodies
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells. Structural diversity has been fast-growing in the bispecific antibody field, creating a plethora of novel bispecific antibody scaffolds, which provide great functional variety. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody. Unlike the conventional monoclonal antibodies, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. In this review, we focus on these two major bispecific types and describe recent advances in the design, production, and quality of these molecules, which will enable this important class of biologics to reach their therapeutic potential.